Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib

JAMA Oncology 2026 Open access

Read full text
Authors: Kim A. Reiss, Mingyi Xia, Mwangala P. Akamandisa, Kurt D’Andrea, Brad Wubbenhorst, Christopher J. Lord, Stephen J. Pettitt, Andrew N J Tutt, T D Brown, Mark H O'Hara, Charles Schneider, Ursina Teitelbaum
+6 more Zain Hannan, Ryan Hood, Rashmi Tondon, Robert H Vonderheide, Susan M Domchek, Katherine L Nathanson
DOI: 10.1001/jamaoncol.2026.0870
Cited by: 1
References: 6

Abstract

This secondary analysis of a nonrandomized clinical trial assesses long-term survival and genomic variants associated with therapeutic resistance in patients receiving maintenance rucaparib with BRCA1 , BRCA2 , or PALB2 germline or somatic pathogenic variants and platinum-sensitive metastatic pancreatic adenocarcinoma.

Fields of Study & Subjects

PARP inhibition in cancer therapy Pancreatic and Hepatic Oncology Research BRCA gene mutations in cancer

Publication details

Journal / source
JAMA Oncology
Publisher
American Medical Association (AMA)
Volume
12
Issue
6
Pages
666–666
Publication date
30 April 2026
Language
EN